Combining computational and experimental approaches: a novel pH-responsive PVA-stabilized MXene nanocarriers/doxorubicin delivery system with enhanced efficacy for targeted lung cancer therapeutics.

While advancements have been made in cancer treatment, achieving effective localized therapy remains a significant challenge. Major obstacles include the inefficiency of drug delivery methods and the side effects linked to traditional chemotherapeutics. In this study, we present an innovative delivery system designed to transport doxorubicin (DOX) directly to the lungs. This system employs PVA-stabilized DOX-loaded MXene, aiming to improve targeted delivery and drug efficacy while minimizing toxicity. Our approach represents a promising advancement in the optimization of cancer therapeutics. Using in silico and computational methods, we evaluated the interactions between PVA, DOX, and MXene. Characterization techniques demonstrated that the synthesized PVA@Mxene/DOX exhibited favorable physicochemical properties. We assessed the anticancer potential of PVA@Mxene/DOX through the MTT assay, in vitro migration assay, and apoptosis assay. The findings revealed that the developed anticancer PVA@Mxene/DOX displayed a layered structure with controlled release kinetics. Notably, it significantly reduced cancer cell growth (P < 0.05), induced apoptosis in cancer cells, and inhibited their migration. These results suggest that PVA@Mxene/DOX holds promise as an effective anticancer agent to enhance lung cancer treatment and improve patient care.